AbbVie Q1 2026 Earnings $ABBV Adj EPS $2.65, est. $2.60 Adj EPS $2.65 vs. $2.46 y/y Net rev. $15.00b, est. $14.73b Rinvoq rev. $2.12b, est. $2.05b Skyrizi revenue $4.48b, est. $4.48b Humira rev $688m, est. $703.4m Imbruvica rev. $556m, est. $577.9m Sees fy adj EPS $14.08 to…
AbbVie Q1 2026 Earnings $ABBV Adj EPS $2.65, est. $2.60 Adj EPS $2.65 vs. $2.46 y/y Net rev. $15.00b, est. $14.73b Rinvoq rev. $2.12b, est. $2.05b Skyrizi revenue $4.48b, est. $4.48b Humira rev $688m, est. $703.4m Imbruvica rev. $556m, est. $577.9m Sees fy adj EPS $14.08 to $14.28, saw $13.96 to $14.16| FJ